Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
Monopar Therapeutics Inc. (MNPR)
Company Research
Source: GlobeNewswire
WILMETTE, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the filing of a provisional patent covering new therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotopes with targeting agents, including Monopar’s uPAR targeting antibody MNPR-101. Highlights of the patent filing include: Composition of Matter: Claims cover a family of linkers, as well as Monopar’s uPAR targeting agents linked with these along with therapeutic radioisotopesStability and Biodistribution: These proprietary new linkers have been created to enhance the stability and biodistribution of Monopar’s array of therapeutic radiopharmaceuticalsVersatility: The newly developed linker family works with a wide range of isotopes and targeting molecules, including small molecules/peptides and antibodies “This provisional patent could enabl
Show less
Read more
Impact Snapshot
Event Time:
MNPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNPR alerts
High impacting Monopar Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
MNPR
News
- Monopar Therapeutics Inc. (NASDAQ: MNPR) had its price target raised by analysts at HC Wainwright from $6.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent DevelopmentsGlobeNewswire
- Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common StockGlobeNewswire
- Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
- Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common StockGlobeNewswire
MNPR
Sec Filings
- 11/8/24 - Form 8-K
- 11/8/24 - Form 10-Q
- 11/6/24 - Form SC
- MNPR's page on the SEC website